Kumar Saurabh, Barbhaiya Chirag R, Sobieszczyk Piotr, Eisenhauer Andrew C, Couper Gregory S, Nagashima Koichi, Mahida Saagar, Baldinger Samuel H, Choi Eue-Keun, Epstein Laurence M, Koplan Bruce A, John Roy M, Michaud Gregory F, Stevenson William G, Tedrow Usha B
From the Arrhythmia Unit (S.K., C.R.B., K.N., S.M., S.H.B., E.-K.C., L.M.E., B.A.K., R.M.J., G.F.M., W.G.S., U.B.T.), Interventional Cardiology and Vascular Medicine, Cardiovascular Division (P.S., A.C.E.), and Division of Cardiac Surgery (G.S.C.), Brigham and Women's Hospital, Boston, MA.
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):606-15. doi: 10.1161/CIRCEP.114.002522. Epub 2015 Apr 29.
Ventricular tachycardia (VT) refractory to antiarrhythmic drugs and standard percutaneous catheter ablation techniques portends a poor prognosis. We characterized the reasons for ablation failure and describe alternative interventional procedures in this high-risk group.
Sixty-seven patients with VT refractory to 4±2 antiarrhythmic drugs and 2±1 previous endocardial/epicardial catheter ablation attempts underwent transcoronary ethanol ablation, surgical epicardial window (Epi-window), or surgical cryoablation (OR-Cryo; age, 62±11 years; VT storm in 52%). Failure of endo/epicardial ablation attempts was because of VT of intramural origin (35 patients), nonendocardial origin with prohibitive epicardial access because of pericardial adhesions (16), and anatomic barriers to ablation (8). In 8 patients, VT was of nonendocardial origin with a coexisting condition also requiring cardiac surgery. Transcoronary ethanol ablation alone was attempted in 37 patients, OR-Cryo alone in 21 patients, and a combination of transcoronary ethanol ablation and OR-Cryo (5 patients), or transcoronary ethanol ablation and Epi-window (4 patients), in the remainder. Overall, alternative interventional procedures abolished ≥1 inducible VT and terminated storm in 69% and 74% of patients, respectively, although 25% of patients had at least 1 complication. By 6 months post procedures, there was a significant reduction in defibrillator shocks (from a median of 8 per month to 1; P<0.001) and antiarrhythmic drug requirement although 55% of patients had at least 1 VT recurrence, and mortality was 17%.
A collaborative strategy of alternative interventional procedures offers the possibility of achieving arrhythmia control in high-risk patients with VT that is otherwise uncontrollable with antiarrhythmic drugs and standard percutaneous catheter ablation techniques.
对抗心律失常药物和标准经皮导管消融技术难治的室性心动过速(VT)预后较差。我们对消融失败的原因进行了特征分析,并描述了该高危组中的替代介入治疗方法。
67例对4±2种抗心律失常药物难治且曾接受过2±1次心内膜/心外膜导管消融尝试的室性心动过速患者接受了经冠状动脉乙醇消融、手术心外膜开窗(Epi-window)或手术冷冻消融(OR-Cryo);年龄为62±11岁;52%的患者发生过室性心动过速风暴。心内膜/心外膜消融尝试失败的原因是壁内起源的室性心动过速(35例患者)、因心包粘连导致心外膜难以进入的非心内膜起源(16例)以及消融的解剖学障碍(8例)。8例患者的室性心动过速为非心内膜起源,且同时存在需要心脏手术的情况。37例患者单独尝试了经冠状动脉乙醇消融,21例患者单独尝试了OR-Cryo,其余患者采用经冠状动脉乙醇消融与OR-Cryo联合(5例患者)或经冠状动脉乙醇消融与Epi-window联合(4例患者)。总体而言,替代介入治疗方法分别使69%和74%的患者消除了≥1种可诱发的室性心动过速并终止了风暴,尽管25%的患者至少发生了1种并发症。术后6个月时,除颤器电击次数(从每月中位数8次降至1次;P<0.001)和抗心律失常药物需求显著减少,尽管55%的患者至少发生了1次室性心动过速复发,死亡率为17%。
替代介入治疗方法的联合策略为控制对抗心律失常药物和标准经皮导管消融技术难治的高危室性心动过速患者的心律失常提供了可能。